Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response

E M van Wezel; J de Bruijne; K Damman; M Bijmolen; A P van den Berg; E A M Verschuuren; G A Ruigrok; A Riezebos-Brilman; M Knoester

doi:10.1093/ofid/ofz346

Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response

Open Forum Infect Dis. 2019 Aug 1;6(8):ofz346. doi: 10.1093/ofid/ofz346.

Authors

E M van Wezel¹, J de Bruijne², K Damman³, M Bijmolen⁴, A P van den Berg⁵, E A M Verschuuren², G A Ruigrok⁶, A Riezebos-Brilman⁷, M Knoester³

Affiliations

¹ Department of Clinical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, The Netherlands.
² Department of Gastroenterology, University of Utrecht, Utrecht University Medical Center, The Netherlands.
³ Department of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands.
⁴ Department of Gastroenterology, University of Groningen, University Medical Center Groningen, The Netherlands.
⁵ Pulmonology and Tuberculosis, University of Groningen, University Medical Center Groningen, The Netherlands.
⁶ Department of Pulmonology, University of Utrecht, Utrecht University Medical Center, The Netherlands.
⁷ Department of Clinical Microbiology, University of Utrecht, Utrecht University Medical Center, The Netherlands.

Abstract

Ribavirin is effective for treating immunocompromised patients with chronic hepatitis E virus infection. However, ribavirin treatment is not always successful. We describe 3 solid organ transplant recipients treated with sofosbuvir and ribavirin after failing ribavirin monotherapy. Complete elimination of hepatitis E virus could not be achieved.

Keywords: chronic hepatitis E; sofosbuvir; solid organ transplant recipients.